Skip to main content
. 2022 Jun 14;25(7):104589. doi: 10.1016/j.isci.2022.104589

Figure 4.

Figure 4

Apln promotes endothelial cell remodeling in vitro and in vivo

(A and B) EC expansion of C166 and EOMA lines treated for 5days with the recombinant Apln-13 peptide at 10μM.

(A) Representative images of DAPI staining of C166 ECs. Scale bar, 100 μm.

(B) Quantification of the total number of C166 and EOMA cells treated with Apln compared to the control medium. (n = 16 cell culture replicates per group).

(C–F) Daily Apln-13 administration at 0.5 μmol/kg/day for 7days in aged mice following cardiotoxin-induced injury in TA muscle. (D) Expression of Pecam1 mRNA by RT-qPCR in whole TA muscles at 3 and 7 days.p.i. and non-injured TA muscles (n = six to seven TA muscles per group). (E) Representative images of CD31 and Laminin immunostaining in CTX-injured TA muscles at 3 days.p.i. Scale bar, 50 μm. (F) Quantification of CD31+ endothelial cells at 3 and 7 days.p.i. in regenerating regions (n = 5 TA muscles per group).

Dashed line indicates the basal level of CD31+ cell per mm2 in non-injured TA muscles (from Figure 3I). In (B), (D) and (I), p values are reported by two-tailed unpaired t-test compared to 0 days.p.i.; n.s represents p > 0.05.